BriaCell Therapeutics Corp
Company Profile
Business description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Contact
235-15th Street
Suite 300, 3rd Floor, Bellevue Centre
West Vancouver
VancouverBCV7T 2X1
CANT: +1 888 485-6340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2026
Employees
12
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
stocks
Our three most overvalued ASX shares
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.70 | 39.80 | -0.44% |
| CAC 40 | 7,765.13 | 30.29 | 0.39% |
| DAX 40 | 23,736.60 | 70.53 | -0.30% |
| Dow JONES (US) | 45,514.95 | 106.34 | -0.23% |
| FTSE 100 | 9,251.15 | 29.71 | 0.32% |
| HKSE | 25,938.13 | 304.22 | 1.19% |
| NASDAQ | 21,798.70 | 91.01 | 0.42% |
| Nikkei 225 | 43,459.29 | 184.52 | -0.42% |
| NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
| S&P 500 | 6,495.15 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,803.50 | 37.40 | -0.42% |
| SSE Composite Index | 3,807.29 | 19.55 | -0.51% |